Cold Agglutinin Disease: Treatment Goals

EP: 1.An Overview of Cold Agglutinin Disease

EP: 2.Types of Autoimmune Hemolytic Anemias

EP: 3.Impact of Cold Agglutinin Disease on Patients

EP: 4.Cold Agglutinin Disease: Impact on Health Care Utilization

EP: 5.Cold Agglutinin Disease: A Differential Diagnosis

Now Viewing

EP: 6.Cold Agglutinin Disease: Treatment Goals

EP: 7.PRO Data & Support for Patients With Cold Agglutinin Disease

EP: 8.Challenges Managing Cold Agglutinin Disease

EP: 9.Cold Agglutinin Disease: Treatment Considerations

EP: 10.Educating Patients and HCPs About Cold Agglutinin Disease

EP: 11.Anti–B-Cell Therapy for Cold Agglutinin Disease

EP: 12.Coverage of Anti–B-Cell Therapies for Cold Agglutinin Disease

EP: 13.Treating Cold Agglutinin Disease With Anti–B-Cell Therapy

EP: 14.Cold Agglutinin Disease: Treatment Gaps

EP: 15.Novel Complement Therapies for Cold Agglutinin Disease

EP: 16.Coverage for Complement Therapies for Cold Agglutinin Disease

EP: 17.Implications for Using Complement Therapies for Cold Agglutinin Disease

EP: 18.Cold Agglutinin Disease: Clinical Pearls

Neil Minkoff, MD: The question that comes to mind is—you’ve identified this, before we even get into the options for treatment—what’s your goal for your patient?

Mihir Raval, MD, MPH: The goals of the treatment I would divide mainly into symptom management, which means we’re looking at correction of underlying anemia that’s predominantly causing that fatigue, tiredness, weakness, or decline in their activities of daily living. That’s the No. 1 treatment. No. 2 is cold-induced symptom management. That means if the patients are having symptoms of extremities, or just as Dr Lorber mentioned about the cold ear and nose tips, those are some of the symptoms that are limiting patients’ activities of daily living, like hanging out with their families and going out to eat during winter months. Those are 2 predominant symptoms that you can manage. The third goal is actually preprocedural correction. Sometimes, patients may have cold agglutinin disease that has to undergo a surgery. That may warrant for some urgent intervention, such as plasma exchange. The fourth treatment goal is long-term management to tackle the underlying problem, the clone that may be causing this problem by looking at either B-cell–directed treatment or by doing some complement-directed treatment, depending on how severe the disease is.

Neil Minkoff, MD: How do you measure the patient’s response? Is it mostly how they feel? Is it a combination of that with lab data? When you decide that you’ve accomplished your goal? Is that a silly question?

Mihir Raval, MD, MPH: No, it’s a very valid question. But as a clinician, when I decide that this patient needs the treatment, my assessment to treatment response is multifocal, so it’s not just 1 area that I’m looking at. I’m looking at lab improvement. Sometimes, those patients’ hemolysis doesn’t completely get better but is good enough that they can have a better quality of life and can be followed periodically to make sure that it’s not worsening. That’s 1 goal: assessing the lab improvement, their hemoglobin improved enough that they are transfusion independent. That’s 1 of the biggest goals. The second goal is, do their symptoms improve enough that they can live a little better life without having cold-related symptoms? Improvement in the fatigue and also simultaneously monitoring for any concerns of progressive lymphoma or autoimmune disease. Those are some of the monitors that I follow to assess the treatment response.

Transcript edited for clarity.